Global Schizophrenia Drugs Market to Grow at a CAGR of 3.9% During 2024-2032, Aided by the Growing Number of Clinical Trials for New Treatments of Schizophrenia

A chronic brain disease called schizophrenia impairs a person's capacity for thought, emotion, and behaviour. The patient may exhibit severely disturbed thinking and behaviour, as well as symptoms like delusions and hallucinations. The schizophrenia drugs market expansion is being driven by growing consumer awareness of mental health.

North America holds a significant market share for this market. According to health reports, approximately 3.7 million Americans, or 1.8% of the adult population between the ages of 18 and 65, experienced schizophrenia spectrum illnesses at some point in their lives. New drug launches and increased R&D for improvements in anti-psychotic medications contribute to the market's expansion of schizophrenia pharmaceuticals in the region.

Continuous research and development support the growth of the market for schizophrenia drug. In January 2024, Arkemas PLC (NASDAQ: ALKS) announced topline findings from a phase 3 open-label extension study. The study evaluated the long-term safety, tolerability, and durability of the treatment effect of LYBALVI® (olanzapine and samidorphan) in patients treated for schizophrenia, schizophreniform disorder, or bipolar I disorder for a maximum of four years after receiving treatment in earlier LYBALVI studies.

In the United States, LYBALVI is licenced for the treatment of adult bipolar I disorder and adult schizophrenia. 523 participants got at least one dosage of LYBALVI in open-label extension research conducted globally, and 35.9% of participants finished the four-year treatment duration. After receiving LYBALVI medication for up to four years, patients' bipolar I disorder or schizophrenia symptoms stayed stable, as indicated by the Clinical Global Impression of Severity (CGI-S) scale (mean change from baseline in CGI-S score of -0.28).

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Therapeutic Class, Route of Administration, Distribution Channels, and Region:

• The market, on the basis of therapeutic class, can be divided into second-generation antipsychotics and third-generation antipsychotics, among others.

• Based on route of administration, the market can be divided into oral and injectables.

• The various distribution channels for schizophrenia drug include hospital pharmacies, retail pharmacies, and online, among others.

• The major regional markets for schizophrenia drug include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• In the US, schizophrenia affects 1.1% of the population, which necessitates schizophrenia drug development and expands the market growth.

• The growing popularity of injectable-based drugs for schizophrenia, especially long-acting injectables, can be attributed to their advantages and reduced side effects. It also cancels out the side effects of oral schizophrenia drugs. UZEDY (risperidone) and INVEGA TRINZA® (paliperidone palmitate) are some of the well-known injectables.

• The growing number of clinical trials for new treatments of schizophrenia and the growing number of industry collaborations in drug development expand the schizophrenia drugs market size. For instance, in October 2022, Royalty Pharma plc collaborated with Merck for a Phase 2b study for the treatment of schizophrenia.

• Approximately 24 million people worldwide suffer from schizophrenia, and only about one-third of cases are properly identified. As a result, researchers are developing a novel category of medications that target different neurotransmitters in an attempt to lessen the negative symptoms of schizophrenia, such as decreased enjoyment, social interaction, and emotional expressiveness.

Key Offerings of the Report:

• The EMR report gives an overview of the global schizophrenia drugs market for the periods (2017-2023) and (2024-2032).

• The report also offers the historical (2017-2023) and forecast (2024-2032) markets for the therapeutic classes, routes of administration, distribution channels, and major regions of schizophrenia drugs.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global schizophrenia drugs market are Eli Lilly and Company, AbbVie Inc., Alkermes PLC, Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Pfizer Inc., AstraZeneca, Bristol Myers Squibb, Sumitomo Dainippon Pharma Co., Ltd., and Vanda Pharmaceuticals Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

Key Highlights of the Report

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790